A detailed history of Morgan Stanley transactions in Volitionrx LTD stock. As of the latest transaction made, Morgan Stanley holds 134,000 shares of VNRX stock, worth $81,740. This represents 0.0% of its overall portfolio holdings.

Number of Shares
134,000
Previous 135,729 1.27%
Holding current value
$81,740
Previous $97,000 4.12%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.72 - $1.19 $1,244 - $2,057
-1,729 Reduced 1.27%
134,000 $101,000
Q4 2023

Feb 13, 2024

SELL
$0.55 - $0.88 $41,027 - $65,644
-74,596 Reduced 35.47%
135,729 $97,000
Q3 2023

Nov 15, 2023

SELL
$0.69 - $1.53 $5,437 - $12,056
-7,880 Reduced 3.61%
210,325 $145,000
Q2 2023

Aug 14, 2023

SELL
$1.39 - $2.02 $25,434 - $36,961
-18,298 Reduced 7.74%
218,205 $303,000
Q1 2023

May 15, 2023

SELL
$1.54 - $2.68 $23,705 - $41,253
-15,393 Reduced 6.11%
236,503 $451,000
Q4 2022

Feb 14, 2023

SELL
$1.63 - $2.6 $206,126 - $328,790
-126,458 Reduced 33.42%
251,896 $612,000
Q3 2022

Nov 14, 2022

SELL
$1.57 - $2.38 $29,638 - $44,929
-18,878 Reduced 4.75%
378,354 $515,000
Q2 2022

Oct 27, 2022

SELL
$1.96 - $3.05 $161,045 - $250,606
-82,166 Reduced 17.14%
397,232 $815,000
Q2 2022

Aug 15, 2022

SELL
$1.96 - $3.05 $161,045 - $250,606
-82,166 Reduced 17.14%
397,232 $815,000
Q1 2022

Oct 27, 2022

BUY
$2.41 - $3.24 $198,020 - $266,217
82,166 Added 20.68%
479,398 $1.44 Million
Q1 2022

May 13, 2022

BUY
$2.41 - $3.24 $23,726 - $31,897
9,845 Added 2.1%
479,398 $1.44 Million
Q4 2021

Feb 14, 2022

SELL
$3.02 - $4.13 $341,127 - $466,508
-112,956 Reduced 19.39%
469,553 $1.48 Million
Q3 2021

Nov 15, 2021

BUY
$2.98 - $3.48 $1.74 Million - $2.03 Million
582,509 New
582,509 $1.81 Million

Others Institutions Holding VNRX

About VOLITIONRX LTD


  • Ticker VNRX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 57,297,000
  • Market Cap $35M
  • Description
  • VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating sampl...
More about VNRX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.